Arcturus Therapeutics enters its third-quarter report with an unusual problem for a cash-burning biotech: the stock has already done a lot of celebrating. Shares have climbed nearly 74% since the last report while the S&P 500 went nowhere, and the rally came without a hard efficacy readout. Management had promised fulsome Phase 2 data and an end-of-Phase 2 regulatory plan for its OTC deficiency drug ARCT-810 in the third quarter. That window has now closed, which makes this release less about the income statement and more about whether the company is delivering on the timeline it set.

The numbers themselves are expected to look like a business in transition. Consensus calls for a loss of $0.60 per share on revenue of about $8.5 million. That loss is roughly 22% wider than the $0.49 posted a year ago, and revenue is projected to fall by about half from $17.2 million. Both declines are largely mechanical, reflecting the termination of the CSL collaboration that once supplied most of the top line. Sequentially the picture is better: revenue would nearly triple from last quarter's $3 million and the loss would narrow from $0.84. Without formal financial guidance, the source of that revenue step-up is worth scrutinizing. Grant funding tied to the pandemic flu program, Thermo Fisher contributions or residual settlement effects would each carry different implications for how durable the figure is.

Cash is the metric that anchors the bull case. Arcturus ended June with $191.5 million and had been burning roughly $39 million per half-year, a pace helped by R&D spending that fell to $17.5 million from $29.6 million a year earlier. Management extended its runway to the end of 2028 last quarter. Validation would look like burn holding near that recent pace even as the company now carries its regained vaccine portfolio on its own. A meaningful jump in spending, or another uptick in legal-driven G&A, would challenge the claim that the CSL exit left Arcturus leaner rather than more stretched.

The operating story rests on two decisions management deliberately framed for the back half of 2026. The first is the ARCT-810 package. Because the study is open-label, lacks a placebo and was not designed to capture hyperammonemic crises, the read hinges on biomarkers, quality of life and, crucially, how regulators react. Clarity on a Phase 3 path would support the more confident tone; vague or delayed regulatory feedback would undercut it. The second is the Phase 3 go or no-go call on cystic fibrosis candidate ARCT-032, guided for the fourth quarter and tied to Thermo Fisher milestone money. Investors should want evidence that the Israel and Turkey sites are enrolling and that the decision remains on schedule. Updates on partnering the regained flu, RSV and other vaccine assets, the Meiji profit-share renegotiation in Japan, and EMA advice for pandemic flu candidate ARCT-2304 would add optionality, but they are secondary to the two rare-disease programs.

Sentiment has swung sharply, moving from moderately bearish before the last report to solidly bullish now. That shift, paired with the rally, means the bar is higher than it was three months ago. The stock trades at $11.23, comfortably above its 200-day average near $8.93 but well below its post-report peak of $17.96, suggesting some enthusiasm has already been tested and partially unwound. Its range since the last report is far wider than the prior quarter's, a sign of a market reacting to catalysts rather than earnings.

In the end, a modest miss or beat against the $0.60 loss estimate will matter little. What determines whether the narrative holds is whether Arcturus shows that the OTC regulatory path is real, the CF decision is on track, and the cash runway through 2028 remains intact despite a fuller standalone pipeline.